Patents Examined by Ruixiang Li
-
Patent number: 11970530Abstract: This disclosure relates to methods of treating homologous recombination (HR) deficient cancers, such as ovarian cancer, fallopian tube cancer, primary peritoneal cancer, breast cancer, and/or pancreatic cancer. This disclosure further relates to preventing, controlling or reducing hypertension and/or proteinuria in a subject receiving a therapeutically effective amount of bevacizumab therapy.Type: GrantFiled: August 11, 2021Date of Patent: April 30, 2024Assignee: ASTRAZENECA ABInventors: Tsveta Petrova Milenkova-Ilieva, Eric Pujade-Lauraine, Isabelle Ray-Coquard
-
Patent number: 11944666Abstract: The present invention provides, among other things, methods of treating post-cardiac injury syndrome (PCIS) or pericarditis, comprising a step of administering to a subject in need of treatment an interleukin-1 receptor-Fc fusion protein at a therapeutically effective dose and an administration interval for a treatment period sufficient to improve, stabilize or reduce one or more signs and symptoms of pericarditis relative to a control.Type: GrantFiled: September 2, 2022Date of Patent: April 2, 2024Assignee: REGENERON PHARMACEUTICALS, INC.Inventors: Eben Tessari, John Paolini
-
Patent number: 11932691Abstract: The present disclosure relates to anti-ROR1 binding proteins, including those that bind to a ROR1 or portion thereof such as an intracellular C terminal portion of a ROR1 protein, and the use of such binding proteins in immunohistochemical and diagnostic methods. Related kits and methods of using the binding proteins are also provided, as are methods of treatment of subjects having diseases or conditions determined to be candidates for such treatments by the binding proteins or methods of this disclosure.Type: GrantFiled: January 25, 2021Date of Patent: March 19, 2024Assignee: Fred Hutchinson Cancer CenterInventors: Ashwini Balakrishnan, Benjamin G. Hoffstrom, Julie Randolph-Habecker, Stanley R. Riddell
-
Patent number: 11932673Abstract: Binding members for sodium channel Nav1.7 and their use in medicine including for treatment of pain or epilepsy. Binding members comprise a fusion protein containing a Nav1.7-binding peptide, e.g., venom toxin peptide or knottin (“donor diversity scaffold domain”) inserted within an antibody variable domain (“recipient diversity scaffold domain”), and a partner domain (e.g., antibody variable domain), optionally wherein the partner domain enhances specificity of binding to Nav1.7 over other sodium channels.Type: GrantFiled: July 11, 2018Date of Patent: March 19, 2024Assignee: MAXION THERAPEUTICS LIMITEDInventors: Aneesh Karatt Vellatt, John McCafferty, Sachin Badrinath Surade, Tim Luetkens, Edward William Masters, Michael Richard Dyson, Damian Colin Bell
-
Patent number: 11926670Abstract: The present invention provides pharmaceutical formulations comprising a human antibody that specifically binds to human interleukin-4 receptor (hIL-4R). The formulations may contain, in addition to an anti-hIL-4R antibody, at least one amino acid, at least one sugar, or at least one non-ionic surfactant. The pharmaceutical formulations of the present invention exhibit a substantial degree of antibody stability after storage for several months.Type: GrantFiled: June 9, 2021Date of Patent: March 12, 2024Assignee: Regeneron Pharmaceuticals, Inc.Inventors: Daniel B. Dix, Xiaolin Tang
-
Patent number: 11921105Abstract: The various aspects presented herein relate to the perfumery industry. More particularly, the various aspects presented herein relate to assays and methods for screening and identifying compositions and/or ingredients that intensify a subject's perception of target odorant compounds based on the use of particular olfactory receptors activated by the target odorant compound.Type: GrantFiled: December 20, 2018Date of Patent: March 5, 2024Inventors: Patrick Pfister, Matthew Rogers, Lily Wu, Christian Margot
-
Patent number: 11912779Abstract: Disclosed herein are polynucleic acid molecules, pharmaceutical compositions, and methods for treating facioscapulohumeral muscular dystrophy (FSHD).Type: GrantFiled: September 15, 2022Date of Patent: February 27, 2024Assignee: AVIDITY BIOSCIENCES, INC.Inventors: Barbora Malecova, Rob Burke, Beatrice Diana Darimont, David Sala Cano
-
Patent number: 11912753Abstract: The invention provides compositions and methods for adoptive T cell therapy in treating a variety of disorders including cancer, infections, and autoimmune disorders. In one embodiment, the invention provides a universal immune receptor (UnivIR) that comprises an extracellular label binding domain, a transmembrane domain, and a cytoplasmic domain or otherwise an intracellular domain.Type: GrantFiled: June 21, 2021Date of Patent: February 27, 2024Assignee: The Trustees of the University of PennsylvaniaInventors: Nathalie Scholler, Katarzyna Urbanska, Daniel J. Powell, Jr.
-
Patent number: 11903998Abstract: Provided herein are methods for preventing or treating cancer in a subject comprising overexpressing at least one Receptor for a lipid agonist, such as G-protein receptors for Resolvin. Such methods may be combined with administering Resolvins, or lipoxins and their analogs, of said Receptors to enhance the pro-resolution effects of the Resolvins, or lipoxins and their analogs, in the local, inflammatory environment where cancer cells are already present.Type: GrantFiled: May 25, 2017Date of Patent: February 20, 2024Assignee: Forsyth Dental Infirmary for ChildrenInventors: Alpdogan Kantarci, Shevali Kansal, Hatice Hasturk, Thomas E. Van Dyke
-
Patent number: 11897929Abstract: The present disclosure encompasses compositions and methods for targeted cytokine delivery. The compositions disclosed herein comprise a cytokine linked to an NKG2D ligand or PD1 ligand and may improve immunotherapy by limiting side effects associated with immunotherapy. The present disclosure also encompasses compositions and methods for recruiting cytotoxic lymphocytes to target cells using NKG2D receptor ligands or PD1 ligands. The compositions disclosed herein comprise a NKG2D receptor ligand and a targeting molecule and may improve immunotherapy by limiting side effects associated with immunotherapy.Type: GrantFiled: April 23, 2021Date of Patent: February 13, 2024Assignee: Washington UniversityInventors: Alexander Sasha Krupnick, Daved Henry Fremont, Eric Reed Lazear, John Westwick
-
Patent number: 11896645Abstract: The invention relates to compounds for use in the treatment of telomere related diseases and/or telomere related medical conditions, particularly wherein said telomere related diseases and/or telomere related medical conditions are cancer and cellular ageing. Particularly, herein is disclosed 37 kDa/67 kDa laminin receptor precursor/high affinity laminin receptor (LRP/LR) and/or a fragment thereof for use in the treatment and/or prevention of cellular ageing.Type: GrantFiled: February 17, 2021Date of Patent: February 13, 2024Assignee: UNIVERSITY OF THE WITWATERSRAND, JOHANNESBURGInventors: Stefan Franz Thomas Weiss, Boitelo Theresiah Letsolo, Kerrilyn Naidoo, Tyrone Chad Otgaar
-
Patent number: 11899014Abstract: The present invention provides sensor cells comprising a receptor that binds to an analyte indicative of the presence of an agent, where binding of the analyte to the receptor triggers a detection event that is indicative of the presence of the agent. In certain embodiments, the detection event is appearance of a reporter detectable by the naked eye. The present invention also provides uses of such sensor cells for detecting the presence of an agent in a sample.Type: GrantFiled: June 19, 2020Date of Patent: February 13, 2024Assignee: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORKInventors: Virginia Wood Cornish, Nili Ostrov, Miguel Jimenez, Sonja Billerbeck
-
Patent number: 11897962Abstract: The present disclosure provides antibodies that specifically bind to human glucocorticoid-induced TNFR family related receptor (GITR) and compositions comprising such antibodies. In a specific aspect, the antibodies specifically bind to human GITR and modulate GITR activity, e.g., enhance, activate or induce GITR activity, utilizing such antibodies. The present disclosure also provides methods for treating disorders, such as cancer and infectious diseases, by administering an antibody that specifically binds to human GITR and modulates GITR activity e.g., enhances, activates or induces GITR activity.Type: GrantFiled: August 21, 2020Date of Patent: February 13, 2024Assignees: AGENUS INC., Memorial Sloan-Kettering Cancer Center, Ludwig Institute for Cancer Research Ltd.Inventors: Volker Seibert, Olivier Léger, Marc Van Dijk, Taha Merghoub, David Schaer, Gerd Ritter, Takemasa Tsuji
-
Patent number: 11890350Abstract: Agents having cytotoxic activity, as well as compositions, uses, and methods relating thereto, are described herein. Certain steroid acid-peptide conjugates or moieties have the ability to induce killing or inhibition of proliferation of mammalian cells, in vitro or in vivo upon administration to a subject. The steroid acid-peptide conjugates include bile acids and bile acid analogs and peptides that may include a nuclear localisation signal or a portion thereof. Also described herein is a method for treating cancer, an autoimmune disease, or any other disease or disorder ameliorated by treatment with an antiproliferative drug in a subject in a subject with the cytotoxic agents described herein.Type: GrantFiled: November 16, 2022Date of Patent: February 6, 2024Assignee: DEFENCE THERAPEUTICS INC.Inventor: Simon Beaudoin
-
Patent number: 11883503Abstract: Provided are compositions and methods for treating cancer comprising the use of a immunoconjugate in combination with a cytotoxic agent or cytotoxic therapy. The immunoconjugate in combination with a cytotoxic agent or cytotoxic therapy shows synergistic effects in cancer treatment.Type: GrantFiled: September 21, 2018Date of Patent: January 30, 2024Assignee: DINGFU BIOTARGET CO., LTD.Inventors: Ting Xu, Yan Luan, Shilong Fu, Songbing Qin, Jian Ding, Kai Fu
-
Patent number: 11879017Abstract: The invention provides chimeric antigen receptors (CARs) comprising an antigen binding domain of human antibody 139, an extracellular hinge domain, a transmembrane domain, and an intracellular domain T cell receptor signaling domain. Nucleic acids, recombinant expression vectors, host cells, populations of cells, antibodies, or antigen binding portions thereof, and pharmaceutical compositions relating to the CARs are disclosed. Methods of detecting the presence of cancer in a host and methods of treating or preventing cancer in a host are also disclosed.Type: GrantFiled: August 24, 2021Date of Patent: January 23, 2024Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Richard A Morgan, Steven A. Rosenberg
-
Patent number: 11873347Abstract: The present invention relates to the field of structural biology. More specifically, the present invention relates to novel antigen-binding chimeric proteins, their uses and methods in three-dimensional structural analysis of macromolecules, such as X-ray crystallography and high-resolution Cryo-EM, and their use as a therapeutic, diagnostic, or imaging tool. Even more specifically, the invention relates to a fusion of a scaffold protein and an antigen-binding domain wherein the scaffold protein of said fusion interrupts the Immunoglobulin domain topology to form a rigid chimer.Type: GrantFiled: October 31, 2018Date of Patent: January 16, 2024Assignees: VIB VZW, VRIJ UNIVERSITEIT BRUSSELInventors: Jan Steyaert, Els Pardon, Tomasz Uchanski, Wim Vranken
-
Patent number: 11866489Abstract: An isolated anti-SCUBE2 antibody or a binding fragment thereof is disclosed. The anti-SCUBE2 antibody comprises an antigen binding region that specifically binds to a target domain located within SCUBE2 (SEQ ID NO: 66) and exhibits a property of inhibiting VEGF-induced angiogenesis. The target domain is selected from the group consisting of the EGF-like motifs 4 to 6 ranging from a.a. position 175 to 323, or the spacer region ranging from a.a. position 441 to 659, or the first cys-rich motif ranging from a.a. position 668 to 725 of SCUBE2 (SEQ ID NO: 66). The anti-SCUBE2 antibody or binding fragment thereof is for use in treating a disease associated with VEGF-induced angiogenesis, or for use in treating a tumor or inhibiting tumor angiogenesis and cancer cell growth in a subject in need thereof.Type: GrantFiled: June 8, 2021Date of Patent: January 9, 2024Assignee: ACADEMIA SINICAInventors: Ruey-Bing Yang, Yuh-Charn Lin
-
Patent number: 11857600Abstract: This invention relates to inhibitors of CXC receptor 4 (CXCR4)-G protein-coupled receptor (GPCR) heteromers (CXCR4-GPCR heteromers) associated with cancers, where CXCR4 forms a functional heteromer with other G protein-coupled receptors (GPCRx). More specifically, this invention relates to GPCRx that form heteromers with CXCR4, which upon co-stimulation with CXCR4 agonists and GPCRx agonists leads to enhanced signaling downstream of CXCR4. This invention also provides for the use of inhibitors of the interacting GPCR partner of the CXCR4-GPCRx heteromer or CXCR4-GPCRx heteromer-specific inhibitors including inhibitors of the formation of the CXCR4-GPCRx heteromer and CXCR4-GPCRx heteromer-specific antibodies, and in the diagnosis and/or therapy for cancer.Type: GrantFiled: May 27, 2020Date of Patent: January 2, 2024Assignee: GPCR THERAPEUTICS, INC.Inventors: DongSeung Seen, Eunhee Kim, Jae-Yeon Jeong, Chang Soo Yang, Milim Lee, SoHui Kim, Won-Ki Huh, Yong Bhum Song, Chul O Park, Hyeryung Park, Jiyeong Lee
-
Patent number: 11851497Abstract: The present disclosure relates to methods for treating or ameliorating one or more symptoms of a disease, such as cancer, by administering combinations of antibodies, or antigen-binding fragments thereof, that bind to CD137, and tumor antigen-targeting antibodies.Type: GrantFiled: November 20, 2018Date of Patent: December 26, 2023Assignee: COMPASS THERAPEUTICS LLCInventors: Robert V. Tighe, III, Ugur Eskiocak